The French drugmaker will pay $500 million to collaborate with Teva on an anti-TL1A therapy for ulcerative colitis and Crohn’s disease.Dive Brief:Sanofi will pay Teva Pharmaceutical $500 million to collaborate on an experimental gut disease treatment, betting the medicine could become a top-selling product in one of the most competitive areas of pharmaceutical drug development.In […]
